Immunologic correlates of spontaneous lymphocyte proliferation in human T-lymphotropic virus infection.
Previously we showed that mononuclear cells from about half of human T-lymphotropic virus (HTLV)-seropositive persons exhibit spontaneous proliferation in vitro. We sought to determine if proliferation was associated with other immunologic changes characteristic of HTLV infection. The parameters assessed were (1) percentages of lymphocytes expressing CD4 and/or CD25 (interleukin-2 receptor), (2) serum levels of soluble CD25, (3) serostatus for other viruses, (4) anti-HTLV antibody levels, and (5) HTLV type determined by polymerase chain reaction or serologic reactivity with type-specific peptides. The proliferation+ HTLV (PROL+) group, proliferation HTLV (PROL-) group, and control group showed similar percentages of CD4+, CD25+, and CD4+CD25+ lymphocytes; serum levels of soluble CD25 were also similar. Antibodies to cytomegalovirus, hepatitis B core, and hepatitis C were present in similar proportions of PROL+ and PROL+ groups. However, a significant association was found between spontaneous proliferation and anti-HTLV antibody levels; sera from 67% of PROL+ persons, but only 18% of PROL- persons, required dilution to yield absorbance values within the linear range of the anti-HTLV antibody assay. In the PROL+ group, persons whose sera required the most dilution had proliferative responses significantly higher than those whose sera required no dilution. The PROL+ and PROL groups were similar with regard to the relative distribution of HTLV-I and HTLV-II infection. These findings indicate that HTLV-related spontaneous lymphocyte proliferation is related to levels of circulating anti-HTLV antibodies, and characterizes both HTLV-I and HTLV-II infection.
Prince
H E
HE
American Red Cross Blood Services, Los Angeles, CA 90006.
Lee
H
H
Jensen
E R
ER
Swanson
P
P
Weber
D
D
Fitzpatrick
L
L
Doyle
M
M
Kleinman
S
S
D000914:Antibodies, Viral / Q000032:analysis / Q000276:immunology; D015704:CD4 Antigens / Q000032:analysis / Q000276:immunology; D002455:Cell Division; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D015480:Deltaretrovirus Antibodies / Q000032:analysis / Q000276:immunology; D006800:Deltaretrovirus Infections / Q000276:immunology / Q000473:pathology*; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000276:immunology; D015367:Human T-lymphotropic virus 2 / Q000235:genetics / Q000276:immunology; D006801:Humans; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology*; D016133:Polymerase Chain Reaction; D015375:Receptors, Interleukin-2 / Q000032:analysis / Q000276:immunology
D000914:Antibodies, Viral; D015704:CD4 Antigens; D015480:Deltaretrovirus Antibodies; D015375:Receptors, Interleukin-2